Ascentage Pharma Group International (AAPG)

TheFly reported on June 15 that Oppenheimer initiated coverage of AAPG with an Outperform rating and a $45 price target.

Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.

Stocks with high upside are rarely obvious at the start. The market usually sees a small company, an unproven business model, or a story that still needs execution.

On January 14, Rodman & Renshaw initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $48 price target, citing the company’s differentiated hematology-focused...

Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...

Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best performing mid cap stocks so far in 2025.

On July 1, Alan McKnight, the CIO at Regions Wealth Management, appeared on CNBC to explain how his biggest worry is currently centered around uncertainty, which he believes leads to volatility.

Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best young stocks to buy and hold for 5 years.

On July 2, Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' to discuss the market's momentum in the second half of 2025.